drugset / Trial / NCT00856310
A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
RandomizedSingle-groupTriple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled single-dose study of the safety and tolerability of intravenously administered REGN475 in healthy volunteers. The primary objective of the study is to assess the safety and tolerability of REGN475. The secondary objectives are to characterize the pharmacokinetic and immunogenicity profiles of REGN475.
Timeline
- Start
- 2009-02
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fasinumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.